Sight Sciences Inc (SGHT) Stock AnalysisSGHTSight Sciences Inc

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Sight Sciences Inc is a good buy right now, primarily due to its recent FDA approval for the TearCare System, which is expected to enhance its market position in dry eye treatment. The current price of $8.55 is below the analyst price target of $8, indicating potential upside. Additionally, the gross margin has improved significantly to 90.96% in Q2 2026, showcasing strong operational efficiency. However, the main risk is the company’s ongoing net losses, with a net income of -4.446 million USD in Q2 2026, which could impact future performance.